TY - JOUR
T1 - Adherence to growth hormone (GH) therapy in naïve to treatment GH-deficient children: data of the Italian Cohort from the Easypod Connect Observational Study (ECOS)
AU - Giordano, Carla
AU - Garofalo, Piernicola
AU - Giordano, Carla
AU - Cavallo, null
AU - Guzzetti, null
AU - Centonze, null
AU - Sacco, Michele
AU - De Luca, Filippo
AU - De Luca, null
AU - Pesce, null
AU - Caruso-Nicoletti, null
AU - De Luca, null
AU - Salerno, null
AU - Greggio, null
AU - Orlando, null
AU - Angeletti, null
AU - Centonze, null
AU - Tafi, null
AU - Bernasconi, null
AU - Di Pietro, null
AU - Cianfarani, null
AU - Parpagnoli, null
AU - Licenziati, null
AU - Della Casa, null
AU - Caruso-Nicoletti, null
AU - Antoniazzi, null
AU - Maghnie, Mohamad
AU - Cardinale, null
AU - Citro, null
AU - Cianfarani, null
AU - Loche, Sandro
AU - Persani, Luca
AU - Bernasconi, Sergio
PY - 2019
Y1 - 2019
N2 - Background: With the use of non-objective measurement, adherence to growth hormone (GH) therapy has been reported suboptimal in a large proportion of patients, and poor adherence has been shown to affect short-term growth response in patients receiving GH treatment. Objective: The Easypod™ electronic device allows objective measurement of adherence. In this study, we report 3-year prospective adherence data of the Italian cohort of naïve GH deficient (GHD) children extrapolated from the Easypod Connect Observational Study (ECOS) database. Patients and methods: Seventy-three GHD children naïve to GH treatment were included in the analysis. 22 Italian centers participated in the study. Results: Mean adherence rate was consistently above 85% across the 3-year observation period. Particularly, mean adherence was 88.5%, 86.6%, and 85.7% after 1, 2 and 3 years, respectively. Mean (± SD) height-SDS increase after the first year was 0.41 (± 0.38). Conclusions: The majority of naïve GHD children starting GH treatment with Easypod maintained an adherence rate > 85% up to 3 years. Easypod is a useful tool to follow-up patients’ adherence allowing timely intervention to improve optimal treatment for these patients.
AB - Background: With the use of non-objective measurement, adherence to growth hormone (GH) therapy has been reported suboptimal in a large proportion of patients, and poor adherence has been shown to affect short-term growth response in patients receiving GH treatment. Objective: The Easypod™ electronic device allows objective measurement of adherence. In this study, we report 3-year prospective adherence data of the Italian cohort of naïve GH deficient (GHD) children extrapolated from the Easypod Connect Observational Study (ECOS) database. Patients and methods: Seventy-three GHD children naïve to GH treatment were included in the analysis. 22 Italian centers participated in the study. Results: Mean adherence rate was consistently above 85% across the 3-year observation period. Particularly, mean adherence was 88.5%, 86.6%, and 85.7% after 1, 2 and 3 years, respectively. Mean (± SD) height-SDS increase after the first year was 0.41 (± 0.38). Conclusions: The majority of naïve GHD children starting GH treatment with Easypod maintained an adherence rate > 85% up to 3 years. Easypod is a useful tool to follow-up patients’ adherence allowing timely intervention to improve optimal treatment for these patients.
UR - http://hdl.handle.net/10447/402221
UR - http://link.springer.com/journal/40618
M3 - Article
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
SN - 0391-4097
ER -